Quest PharmaTech begins Phase I/II of oregovomab for ovarian cancer

The OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) began a Phase I/II trial of oregovomab (OvaRex Mab, OvaRex) plus Hiltonol (Poly-ICLC) from Oncovir Inc. (Washington, D.C.) to treat recurrent ovarian cancer.

The open-label, U.S. trial will evaluate 2 mg IV oregovomab at weeks 0, 3, 6 and 9 and once at week 16 with Hiltonol adjuvant. The primary endpoint is safety. Secondary endpoints include cellular immune response and overall survival (OS). The trial is expected to enroll about 10 patients...